These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 31648843)
41. Cognitive deficits in adolescents with schizophrenia undergoing antipsychotic treatment. Chabrol H; Peresson G; Bonnet D Am J Psychiatry; 1999 Mar; 156(3):497-8. PubMed ID: 10080578 [No Abstract] [Full Text] [Related]
42. Cognitive function and social abilities in patients with schizophrenia: relationship with atypical antipsychotics. Tyson PJ; Laws KR; Flowers KA; Tyson A; Mortimer AM Psychiatry Clin Neurosci; 2006 Aug; 60(4):473-9. PubMed ID: 16884450 [TBL] [Abstract][Full Text] [Related]
43. [Blonanserin in the treatment of schizophrenia]. Tenjin T; Miyamoto S Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596 [TBL] [Abstract][Full Text] [Related]
44. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. Friedman JI; Ocampo R; Elbaz Z; Parrella M; White L; Bowler S; Davis KL; Harvey PD J Clin Psychopharmacol; 2005 Jun; 25(3):237-42. PubMed ID: 15876902 [TBL] [Abstract][Full Text] [Related]
45. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Newman-Tancredi A; Cussac D; Depoortere R Curr Opin Investig Drugs; 2007 Jul; 8(7):539-54. PubMed ID: 17659474 [TBL] [Abstract][Full Text] [Related]
46. Aripiprazole: what is the role of dopamine D(2) receptor partial agonism? Kessler RM Am J Psychiatry; 2007 Sep; 164(9):1310-2. PubMed ID: 17728411 [No Abstract] [Full Text] [Related]
47. The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment. Ribeiro-Santos R; de Campos-Carli SM; Ferretjans R; Teixeira-Carvalho A; Martins-Filho OA; Teixeira AL; Salgado JV Nord J Psychiatry; 2020 Apr; 74(3):187-193. PubMed ID: 31738648 [No Abstract] [Full Text] [Related]
48. The role of cognition in the risk--benefit and safety analysis of antipsychotic medication. Borison RL Acta Psychiatr Scand Suppl; 1996; 389():5-11. PubMed ID: 8985471 [TBL] [Abstract][Full Text] [Related]
49. Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. McCreary AC; Newman-Tancredi A Curr Pharm Des; 2015; 21(26):3725-31. PubMed ID: 26044980 [TBL] [Abstract][Full Text] [Related]
50. Different MK-801 administration schedules induce mild to severe learning impairments in an operant conditioning task: role of buspirone and risperidone in ameliorating these cognitive deficits. Rapanelli M; Frick LR; Bernardez-Vidal M; Zanutto BS Behav Brain Res; 2013 Nov; 257():156-65. PubMed ID: 24095879 [TBL] [Abstract][Full Text] [Related]
51. Repurposing Drugs for Cognition in Schizophrenia. Yang YS; Marder SR; Green MF Clin Pharmacol Ther; 2017 Feb; 101(2):191-193. PubMed ID: 27706797 [TBL] [Abstract][Full Text] [Related]
52. British Association for Psychopharmacology--2008 Summer Meeting. Jenkins TA IDrugs; 2008 Oct; 11(10):720-3. PubMed ID: 18828070 [No Abstract] [Full Text] [Related]
53. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. Tuplin EW; Holahan MR Curr Neuropharmacol; 2017 Nov; 15(8):1192-1207. PubMed ID: 28412910 [TBL] [Abstract][Full Text] [Related]
54. Buspirone for autistic disorder in a woman with an intellectual disability. Brahm NC; Fast GA; Brown RC Ann Pharmacother; 2008 Jan; 42(1):131-7. PubMed ID: 18056831 [TBL] [Abstract][Full Text] [Related]
55. Anxiety disorder. Gale C; Oakley-Browne M BMJ; 2000 Nov; 321(7270):1204-7. PubMed ID: 11073514 [No Abstract] [Full Text] [Related]